×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Media

Amgen Perspectives

Read our submitted letters to editors and responses to Amgen news.

Statements and Responses

December 4, 2017
Amgen Response to ICER’s Review of Migraine Treatments: “Open Input”

November 30, 2017
Amgen’s Statement on Cost Effectiveness of KYPROLIS® (carfilzomib) Compared to Velcade® (bortezomib) in Relapsed or Refractory Multiple Myeloma, Published in Expert Review of Hematology

October 26, 2017
Amgen Statement on the Economic Benefit of XGEVA® (denosumab) Versus Zoledronic Acid in the Prevention of Bone Complications in Multiple Myeloma

October 25, 2017
Amgen Provides Update on Status of Puerto Rico Operations

October 6, 2017
Amgen Provides Update on Status of Puerto Rico Operations

October 5, 2017
Amgen Statement on Appeals Court Decision on PCSK9 Antibody Patents

September 25, 2017
Amgen Response to ICER’s Proposed Adaptation of the ICER Value Framework for the Assessment of Treatments for Ultra-Rare Conditions

August 31, 2017
Amgen Response to ICER’s Draft Scoping Document on CAR-T Therapy for B-Cell Cancers

June 30, 2017
Amgen’s Position on Orphan Drugs and ICER’s Orphan Drug Assessment

June 2, 2017
Amgen’s Response to the Institute for Clinical and Economic Review (ICER) Draft Report on Anabolic Therapies for Osteoporosis in Postmenopausal Women: Effectiveness and Value

May 5, 2017
Amgen Response to ICER's Updated Value Assessment Framework - Recommendations for Value Assessment of PCSK9 Inhibitors

Apr. 27, 2017
Amgen Statement and Response to ICER Revised Value Framework Proposal and Osteoporosis Revised Scoping Document

Apr. 23, 2017
Amgen Response to Washington State Health Technology Assessment (HTA) Program's Draft Evidence Report on the Treatment of Chronic Migraines and Chronic Tension-type Headache

Apr. 3, 2017
Amgen’s Response to ICER’s Call for Comments on its “Updated” Value Framework - Executive Summary

Feb. 16, 2017
Amgen Statement and Response to ICER Rheumatoid Arthritis Draft Evidence Report

Dec. 28, 2016
Amgen Introduces New Value-Based Pharmacy Benefits Insurance Provision for U.S. Staff Members

Oct. 20, 2016
Amgen Response to ICER Plaque Psoriasis Draft Evidence Report

Sep. 12, 2016
Amgen Response to ICER’s Call for Comments on its Value Assessment Framework

Sep. 9, 2016
Amgen Statement on the Clinical and Economic Value of BLINCYTO® (Blinatumomab) in Treating Adults With Relapsed or Refractory Philadelphia Chromosome Negative B-Cell Precursor Acute Lymphoblastic Leukemia